Odyssey Therapeutics (ODTX): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
7 concentrated managers hold it (+4 vs last quarter) with a median weight of 0.5%. 2 officers or directors bought in 6 months.
Who owns Odyssey Therapeutics?
Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): FMR, 10.2% (13G filed Jun 5, 2026), SR One Capital Management, 8.0% (13D filed May 18, 2026), Tpg Gp A, 7.8% (13D filed May 18, 2026), Jeito II S.L.P., 7.8% (13D filed May 15, 2026) and Lightspeed Venture Partners XV-B (Ignite), 7.6% (13G filed May 18, 2026). George Simeon is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were FMR (10.8% of the shares), SR One Capital Management (7.9%) and Tpg Gp A (7.7%).
Which institutions hold the most Odyssey Therapeutics shares?
Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:
- 1. FMR: 10.8%
- 2. SR One Capital Management: 7.9%
- 3. Tpg Gp A: 7.7%
- 4. Lightspeed Management Company, L.l.c: 7.5%
- 5. Orbimed Advisors: 6.2%
- 6. Sanofi: 4.1%
- 7. Deerfield Management: 2.2%
- 8. Sands Capital Alternatives: 1.8%
- 9. Hhlr Advisors: 1.7%
- 10. General Catalyst Group Management: 1.7%
How much of Odyssey Therapeutics do institutions own?
The 59 institutions that file 13F reported 72.6% of the shares as of Jun 30, 2026.
Sources:13G by FMR (Jun 5, 2026) ↗13D by SR One Capital Management (May 18, 2026) ↗13D by TPG GP A (May 18, 2026) ↗13D by Jeito II S.L.P. (May 15, 2026) ↗13G by Lightspeed Venture Partners XV-B (Ignite) (May 18, 2026) ↗All of the company's proxy statements on EDGAR ↗
13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Jun 12, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers: 4 opened · 0 exited = +4 (plus 3 who received it in a spin-off)
Net flow in the quarter: +$37.2M (+2.0 M shares) · bought $37.2M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Deerfield ManagementSpin-off$19.6M0.2%
- Hhlr AdvisorsNewly listed$15.6M1.9%+0.9 pp
- Vivo CapitalSpin-off$10.8M1.0%
- EcoR1 CapitalNewly listed$10.4M0.5%+0.4 pp
- Logos Global ManagementSpin-off$9.8M0.4%
- Redmile GroupNewly listed$8.0M0.5%+0.5 pp
- Cormorant Asset ManagementNewly listed$3.3M0.2%+0.2 pp
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of ODTX (all 13F filers)
- FMR5.2 MInvestment firm+5.2 M
- SR One Capital Management3.8 MPrivate equity or venture capital+3.8 M
- TPG Gp A3.7 MPrivate equity or venture capital+3.7 M
- Lightspeed Management Company, L.l.c3.6 MPrivate equity or venture capital+3.6 M
- Orbimed Advisors3.0 MInvestment firm+3.0 M
- Sanofi2.0 MOperating company+2.0 M
- Deerfield Managementconcentrated1.0 MInvestment firm+1.0 M
- Sands Capital Alternatives875 KPrivate equity or venture capital+875 K
- Hhlr Advisorsconcentrated832 KInvestment firm+832 K
- General Catalyst Group Management810 KPrivate equity or venture capital+810 K
- Shares
- 5.2 M
- Change
- +5.2 M
See more
- Type
- Investment firm
- Value
- $96.9M
- Shares
- 3.8 M
- Change
- +3.8 M
See more
- Type
- Private equity or venture capital
- Value
- $71.0M
- Shares
- 3.7 M
- Change
- +3.7 M
See more
- Type
- Private equity or venture capital
- Value
- $69.0M
- Shares
- 3.6 M
- Change
- +3.6 M
See more
- Type
- Private equity or venture capital
- Value
- $67.5M
- Shares
- 3.0 M
- Change
- +3.0 M
See more
- Type
- Investment firm
- Value
- $56.2M
- Sanofi
- Shares
- 2.0 M
- Change
- +2.0 M
See more
- Type
- Operating company
- Value
- $37.3M
- Deerfield Managementconcentrated
- Shares
- 1.0 M
- Change
- +1.0 M
See more
- Type
- Investment firm
- Value
- $19.6M
- Shares
- 875 K
- Change
- +875 K
See more
- Type
- Private equity or venture capital
- Value
- $16.4M
- Hhlr Advisorsconcentrated
- Shares
- 832 K
- Change
- +832 K
See more
- Type
- Investment firm
- Value
- $15.6M
- General Catalyst Group Management
- Shares
- 810 K
- Change
- +810 K
See more
- Type
- Private equity or venture capital
- Value
- $15.2M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 72.6% of the shares · top 10: 51.7% · in index firms: 4.3% of the institutional total
Shares reported by the 59 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Jun 12, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
Balance sheet only, for now. ODTX has not yet filed its first annual report (10-K) with the SEC, so there are no 12-month figures (revenue, margins, earnings and cash flow). We show the balance sheet from its latest filing; once the 12-month figures are available, this section fills in automatically.
- Cash and equivalents
- $80.6M
- Investments
- $306M
- Shareholders' equity
- $376M
Balance sheet figures the company filed with the SEC (10-Q or 10-K), in dollars. Net debt = total debt − cash − investments; when negative, the company has more cash than debt (net cash). How each figure is calculated
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Unregistered sale of equity securities (Item 3.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Kodiak SciencesKOD · 7 managers
- Rapport TherapeuticsRAPP · 7 managers
- Research Alliance Corporation IIIRACC · 7 managers
- Achieve Life SciencesACHV · 6 managers
- Artiva BiotherapeuticsARTV · 6 managers
- GeneDx HoldingsWGS · 8 managers